,id,ticker,title,category,content,date,provider,url,article_id
1511,223026,DYSL,Dynasil and Cook Bio team up to advance hemostasis product,news,Dynasil  NASDAQ DYSL  commits an additional  1 2M investment in subsidiary Xcede Technologies to support the advancement of the Xcede Patch  a bioabsorbable mesh patch used during surgical procedures to stop bleeding  hemostasis  Cook Biotech will manage the first in human study on behalf of Xcede in exchange for a secured loan of  1 5M  Dynasil Chairman and CEO Peter Sulick and his family have invested an additional  450K in the effort Preclinical work will begin this quarter followed by a clinical trial in 2017 ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/dynasil-and-cook-bio-team-up-to-advance-hemostasis-product-442285,442285
1512,223027,DYSL,Technology   Top Gainers   Losers as of 2 55 pm,news,Gainers  DYSL  18   MTBC  17   I  16   VNET  14   SMSI  12  Losers  SQNS  37   SHOP  11   VERI  11   IDT  9   VJET  7   Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/technology--top-gainers--losers-as-of-255-pm-536911,536911
1538,223053,DYSL,Dynasil Corporation of America reports FY results,news,Dynasil Corporation of America  NASDAQ DYSL   FY EPS of  0 13Revenue of  37 28M   14 2  Y Y Shares  3 41  Press ReleaseNow read ,2017-12-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/dynasil-corporation-of-america-reports-fy-results-1016014,1016014
